Home > Oncology > SABCS 2021 > HR-positive/HER2-negative Breast Cancer > Promising anti-tumour activity of the CDK7-inhibitor samuraciclib plus fulvestrant

Promising anti-tumour activity of the CDK7-inhibitor samuraciclib plus fulvestrant

Presented By
Prof. Charles Coombes, Imperial College London, UK
Conference
SABCS 2021
Efficacy of second-line treatment options for patients with oestrogen receptor (ER)-positive/HER2-negative metastatic breast cancer who progress on an aromatase inhibitor plus CDK4/6 inhibitor is poor. In a first-in-human, phase 2 trial, samuraciclib in combination with fulvestrant showed promising activity. At the moment, there is no current agreed standard of care treatment for woman with ER-positive/HER2-negative metastatic breast cancer who progress on first-line treatment with CDK4/6 inhibitor plus aromatase inhibitor or selective oestrogen receptor degrader (SERD) [1-3]. CDK7 inhibition is a promising therapeutic strategy in cancer because it acts as a regulator of the cell cycle, transcription, and endocrine receptor signalling. Pre-clinical breast cancer models indicate the potential for synergy when the CDK7 inhibitor samuraciclib is combined with fulvestrant [4]. Prof. Charles Coombes (Imperial College London, UK...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on